How should a chronic myeloid leukemia patient who was off therapy after achieving an undetectable BCR‑ABL level be managed now that the disease is detectable again after six months?

Restart TKI Therapy Immediately

For a CML patient who achieved undetectable BCR-ABL off treatment but now has detectable disease at 6 months, you should restart the same TKI that previously achieved deep molecular response. This is the standard approach supported by current guidelines and clinical evidence 1, 2.

Immediate Management Algorithm

1. Confirm Molecular Recurrence

• Repeat BCR-ABL1 testing immediately to confirm the result
• Use RT-qPCR on the International Scale (BCR-ABL1IS) 1
• Document the exact BCR-ABL1IS level to establish baseline for monitoring

2. Restart TKI Without Delay

• Resume the same TKI at the same dose that previously achieved deep molecular response 3
• Do not wait for loss of major molecular response (MMR, defined as >0.1% BCR-ABL1IS) to restart therapy
• The 2025 ELN guidelines recommend molecular monitoring every 3 months during treatment 1

3. Monitoring Schedule After Restart

• Check BCR-ABL1 levels monthly initially until you confirm declining transcript levels
• Once MMR is re-achieved, transition to every 3 months 1
• Most patients who restart TKI after molecular relapse regain deep molecular response, typically within 7.3 months 3

Critical Evidence and Rationale

The loss of MMR (BCR-ABL1IS >0.1%) has been validated as a safe trigger for restarting therapy 3. However, waiting until MMR loss is not mandatory—any confirmed detectable disease after treatment-free remission (TFR) warrants discussion about restarting therapy.

Key data from the A-STIM study showed:

• 36% of patients lost MMR after stopping imatinib, with median time to loss of 4 months 3
• All patients who restarted TKI regained response
• Median time to second complete molecular response was 7.3 months 3

Important Caveats and Pitfalls

Do Not Delay Restart

A critical case report from 2026 demonstrates the danger of delaying TKI restart: A patient who declined to restart therapy after losing deep molecular response progressed to lymphoid blast crisis within 2 months of detectable BCR-ABL1 at 0.08% IS 4. While rare, this underscores that molecular recurrence can occasionally precede rapid progression.

Expect Fluctuations

Approximately 31% of patients show fluctuating BCR-ABL1 transcript levels below the MMR threshold after stopping therapy 3. However, any confirmed detectable disease represents molecular recurrence and should prompt treatment discussion.

Persistent Leukemic Cells

Even patients maintaining apparent complete molecular response off therapy harbor residual leukemia detectable by highly sensitive DNA PCR 5. This explains why molecular recurrence is common (40-60% of patients) and typically occurs within the first 6 months 6.

Expected Outcomes

Nearly all patients (>95%) who restart TKI after molecular relapse regain deep molecular response 6, 3. The prognosis remains excellent with prompt reinitiation of therapy. Treatment-free remission can potentially be attempted again in the future if sustained deep molecular response is re-achieved for an adequate duration (typically ≥2 years).

What NOT to Do

• Do not switch to a different TKI unless the original TKI is contraindicated or poorly tolerated
• Do not perform mutation analysis at this stage—it's only indicated if the patient fails to respond to TKI restart
• Do not wait for symptoms or hematologic changes to restart therapy
• Do not allow patient hesitancy to delay restart given the blast crisis risk, even if rare 4